Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Launches US Recall of Natpara Parathyroid Hormone
September 9, 2019
- Lonsurf Gets European Nod for Gastric Cancer
September 9, 2019
- To Counter Latuda Patent Cliff, Sumitomo Dainippon Poised to Buy 5 “Vants” Companies from Roivant
September 9, 2019
- Labor Union Urges MSD Japan to Make Convincing Case on Job Cuts
September 6, 2019
- MHLW Lifts All-Case PMS Requirement for Pfizer’s Xeljanz for RA Treatment
September 6, 2019
- Keytruda Continues to Enjoy Top Title in August Sales Ranking: Encise
September 6, 2019
- Japan Pharma Market Likely to Shrivel 0.7% Annually in Next 5 Years: IQVIA
September 5, 2019
- Roche/Chugai’s Rozlytrek, AstraZeneca COPD Combos and More Hit Shelves
September 5, 2019
- Anges, Mitsubishi Tanabe to Launch Gene Therapy Collategene on Sept. 10
September 5, 2019
- Candesartan Generics OK'ed for Pediatric Use, Now Offer Full Indications
September 5, 2019
- Edoxaban/Clopidogrel Combo Shows Non-Inferiority against Warfarin Triplet in AF: Daiichi Sankyo
September 5, 2019
- 1st Schizophrenia Patch Drug to Hit Japan Market on Sept. 10: Sumitomo Dainippon
September 4, 2019
- Latuda Makes Debut in China: Sumitomo Dainippon
September 4, 2019
- 70% of Japanese ACS Patients Fail to Hit LDL-C Management Goal in Observational Study: Sanofi
September 4, 2019
- Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
- Higher Rate of Resistance to Xofluza Seen in Younger Children: Shionogi
September 3, 2019
- Astellas Grabs Global Rights to RIKEN’s aAVC Technology in Oncology
September 3, 2019
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
- Kowa Gears Up for Glanatec PII Trial in US
September 3, 2019
- Japan Approves Zykadia’s Smaller Film-Coated Tablets
September 3, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…